German Ambassador inaugurates Boehringer Ingelheim new Cairo office
Boehringer Ingelheim achieved net sales of around 17.5 billion euros worldwide at the end of 2018
With the attendance of His Excellency Cyrill Nunn, Ambassador to the German Missions in the Arab Republic of Egypt as well as members of local medical associations gathered officially to inaugurate the new office, Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, during its press conference, located at the heart of the 5th Settlement. The company has had a presence in Egypt through a scientific office, and today’s event marks the launch of its new commercial legal entity across the country. The attendees noted that the new office opening marks an important milestone in Boehringer Ingelheim’s longstanding history in Egypt, and at the same time, is a reflection of the country’s robust infrastructure, accessibility and central regional prominence.
Yasser Farghali, Boehringer Ingelheim’s General Manager and Head of Human Pharma for Egypt and the LINEA (Levant, Iraq, Near East Africa ) said, “The launch of the new office and second legal entity marks a new chapter in our journey in Egypt, a country where Boehringer Ingelheim has had a longstanding legacy that dates back to 1961. The opening of our new office mirrors the continued upward growth strategy the country is experiencing, by providing a strategic platform for expanding access to our key therapeutic innovations in human and animal health. It will further harness the recent economic and regulatory reforms that are benefitting the entire healthcare ecosystem to support the neighboring region.” “Egypt is a crucial market in the region, and an important hub in our global network. We are focused on delivering international best practices, innovative medical trends, while also ramping up our research and development capabilities, to address the diverse needs of patients in the country and region. The future is promising. We look forward to continuing delivering on our promise by increasing the scale of our commitment towards driving more innovative solutions in our main therapy areas, while also continue building on our leadership position across the animal health business by becoming a center of excellence in Egypt and the wider region,” added Farghali.
Some of the key notable achievements of Boehringer Ingelheim in Egypt include the roll out its Angel’s Initiative which aims to improve and maintain the quality of existing stroke centers. Together with the local medical community, the Angel’s Initiative is focused on building a network of not less than 500 stroke-ready centers to improve care management protocols.
To spread awareness, Boehringer Ingelheim facilitated key initiatives that included a national awareness program with the endorsement of prominent medical and social figures, as well as driving an ambulance team training and bridging the knowledge gap by reaching out to universities and shedding light on key stroke management innovations.
In human health, the company pioneers in driving key innovative medical solutions across cardio-metabolic including diabetes type 2, anti-coagulations, stroke management, hypertension as well as respiratory diseases from Egypt to support the surrounding region. Furthermore, the company continues to focus on providing a holistic approach to type 2 diabetes management by driving access to key innovations that document cardiovascular protection, which reduces cardiac events in patients with type 2 diabetes. Boehringer Ingelheim is planning more launches in the coming year in Egypt to complement its current portfolio and help people living with type 2 diabetes live healthier and safer lives.
In Animal Health, Boehringer Ingelheim enjoys a leadership market position. As a leader in animal health management, Boehringer Ingelheim has introduced key innovations and training curriculums that aim to increase knowledge around vaccine handling, storage, preparation and applications, together with key local solutions and applications. The company supplies more than 11% of the Egyptian market animal health vaccination needs and solutions with a premium position in poultry and veterinary public health.
In specific, Boehringer Ingelheim Animal Health has introduced the In-Ovo Jector, as a strategic initiative for its poultry business in Egypt. This is a landmark milestone and is fully in line with the company’s goal to provide the best services to hatcheries as vaccination equipment is an integral part of its value proposition.
Egypt represents a cornerstone in Boehringer Ingelheim’s operations. The company’s story, which began more than five decades ago, has evolved into sheer dedication towards building a robust business that is in line with the country’s strong infrastructure, accessibility and central regional prominence.
